Ocrevus (ocrelizumab) is a newly FDA-approved therapy for multiple sclerosis. It can be used to treat two forms of the disease: relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
As with all medications and therapies, there is a risk of side effects and infections. As Ocrevus is administered via intravenous infusions, this carries certain risks. The healthcare team that oversees the IV infusion will monitor patients for an hour after the procedure, but many side effects could take up to 24 hours to occur. Some of the risks of the IV infusion according to Genentech, the makers of Ocrevus, include:
- Rash or Hives
- Facial Flushing
- Fatigue or tiredness
- Trouble breathing or shortness of breath
- Coughing or wheezing
- Sore throat
- Feeling faint or dizzy
- Racing heart beat
- Swelling of the throat
It is not known if Ocrevus is a safe therapy for children to take, and the effects on pregnant women and breast milk have yet to be established.